- February 05, 2012
- 02:28 PM CET
- search
- T&C's
- Disclaimer
- PRIVACY POLICY
- Imprint
- RSS
- ©2012 EVOTEC
- Loading...
Top Story
Ad hoc: Evotec and Roche agree to develop compound that could slow the progression of Alzheimer’s disease
Evotec AG and Roche AG today announced that they have entered into an agreement for the development and commercialisation of Evotec’s MAO-B inhibitor...
- read moreAd hoc:Evotec acquires compound management business from Galapagos
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange, TecDAX, ISIN: DE 000 566480 9) and Galapagos NV (Euronext: GLPG) today announced that Evotec has acquired Compound Focus, Inc., the compound management business of BioFocus, a Galapagos Compa...
- read moreAd hoc: Phase II study with NR2B sub-type selective NMDA antagonist in treatment-resistant depression voluntarily terminated
18 May 2011 - Evotec AG and Roche today decided to voluntarily terminate the first proof-of-concept study in treatment-resistant depression with their NR2B sub-type selective NMDA antagonist EVT 101.
- read more
Loading weather report...
Events
Feb 04, 2012 - 1st annual conference & exhibition SLAS 2012
Feb 07, 2012 - UBS 22nd Annual Healthcare Conference
Company Presentation January
Building integrated and high value drug discovery alliances
2012-01_Evotec_Company Presentation_January (1,33 MB)
Want to read some older articles?
- visit the archive